SEARCH

SEARCH BY CITATION

References

  • 1
    Thompson HSG, Staines NA. Gastric administration of type II collagen delays the onset and severity of collagen-induced arthritis in rats. Clin Exp Immunol 1986; 64:5816.
  • 2
    Thompson HSG, Harper N, Bevan DJ, Staines NA. Suppression of collagen induced arthritis by oral administration of type II collagen: changes in immune and arthritic responses mediated by active peripheral suppression. Autoimmunity 1993; 16:18999.
  • 3
    Nagler-Anderson C, Sober LA, Robinson ME, Siskind GW, Thorbecke GJ. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci USA 1986; 83:74436.
  • 4
    Bitar DM, Whitacre CC. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. Cell Immunol 1988; 112:36470.
  • 5
    Higgins PJ, Weiner HL. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J Immunol 1988; 140:4405.
  • 6
    Nussenblatt RB, Caspi RR, Mandi R, Chan C-C, Roberge F, Lider O, Weiner HL. Inhibition of S-antigen induced experimental uveoretinitis by oral induction of tolerance with S-antigen. J Immunol 1990; 144:168995.
  • 7
    Dick AD, Cheng YF, McKinnon A, Liversedge J, Forrester JV. Nasal administration of retinal antigens suppresses the inflammatory response in experimental allergic uveoretinitis. A preliminary report of intranasal induction of tolerance with retinal antigens. Brit J Ophthalmol 1993; 77:1715.
  • 8
    Zhang ZJ, Lee CSY, Lider O, Weiner HL. Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen. J Immunol 1990; 145:248993.
  • 9
    Thompson SJ, Thompson HSG, Harper N, Day MJ, Coad AJ, Elson CJ, Staines NA. Prevention of pristane-induced arthritis by oral administration of type II collagen. Immunology 1993; 79:1527.
  • 10
    Yoshino S, Quattrocchi E, Weiner HL. Oral administration of type II collagen suppresses antigen-induced arthritis in Lewis rats. Arthritis Rheum 1995; 38:1092100.
  • 11
    Trentham DE, Dynesius-Trentham RA, Orav EJ et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993; 261:17279.
  • 12
    Sieper J, Kary S, Sörensen H et al. Oral collagen II treatment in early rheumatoid arthritis: a double-blind placebo-controlled randomized trial. In press.
  • 13
    Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL. Suppressor T cell generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transfroming growth factor β after antigen-specific triggering. Proc Natl Acad Sci USA 1992; 89:4215.
  • 14
    Weiner HL, Friedman A, Miller A et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Ann Rev Immunol 1994; 12:80937.
  • 15
    Croitoru C, Bienenstock J. Characteristics and functions of mucosa-associated lymphoid tissue. In: OgraPL, StroberW, MesteckyJ, McGheeJR, LammME, BenenstockJ, eds. Handbook of mucosal immunology. London : Academic Press,1994; 1419.
  • 16
    Kuper CF, Koornstra PJ, Hameleers DMH et al. The role of nasopharyngeal lymphoid tissue. Immunol Today 1992; 13:21924.
  • 17
    Zhang ZJ, Al-Sabagh A, Lorenzo C, Trentham D, Weiner HL. Suppression of adjuvant and collagen arthritis by aerosol administration of collagen type II. Arthritis Rheum 1990; 33:S106.
  • 18
    Metzler B, Wraith DC. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Intl Immunol 1993; 5:115965.
  • 19
    Holmdahl R, Karlsson L. Rapid method to determine structural polymorphism of rat major histocompatibility complex class II genes. Transplant Proc 1993; 25:2770.
  • 20
    Butler WT, Finch JE, Millar EJ. The covalent structure of cartilage collagen. Evidence for sequence heterogeneity of bovine α1(II) chains. J Biol Chem 1977; 252:63943.
  • 21
    Seyer JM, Hasty KA, Kang AH. Covalent structure of collagen. Amino acid sequence of an arthritic cyanogen bromide peptide from type II collagen of bovine cartilage. Eur J Biochem 1989; 181:15973.
  • 22
    Bray AM, Maeji NJ, Geysen HM. The simultaneous multiple production of solution phase peptides; assessment of the Geysen method of simultaneous peptide synthesis. Tetrahedron Letters 1990; 31:58114.
  • 23
    Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluoromethoxycarbonyl amino acids. Int J Peptide Protein Res 1990; 35:161214.
  • 24
    Holmdahl R, Jansson L, Andersson M, Larsson E. Immunogenetics of type II collagen autoimmunity and susceptibility to collagen arthritis. Immunology 1988; 65:30510.
  • 25
    Michaelsson E, Anderson M, Engstrom A, Holmdahl R. Identification of an immunodominant type II collagen peptide recognised by T cells in H-2q mice: self tolerance at the level of determinant selection. Eur J Immunol 1992; 22:181925.
  • 26
    Ku G, Kronenberg M, Peacock DJ et al. Prevention of experimental autoimmune arthritis with a peptide fragment of type II collagen. Eur J Immunol 1993; 23:5919.
  • 27
    Ye XJ, Terato K, Myers L, Brand DD, Kang A, Cremer MA. Suppression of collagen-induced arthritis in BB rats by synthetic peptide of an immunodominant T cell epitope of bovine type II collagen. Arthritis Rheum 1994; 37 (Suppl.):S396.
  • 28
    Myers LK, Seyer JM, Stuart JM, Kang AH. Identification of an immunosuppressive epitope of type II collagen that confers protection against collagen-induced arthritis. J Exp Med 1989; 170:19992010.
  • 29
    Meyers LK, Cooper SW, Terato K, Seyer JM, Stuart JM, Kang AH. Identification and characterization of a tolerogenic T cell determinant within residues 181-209 of chick type II collagen. Clin Immunol Immunopathol 1995; 75:3338.
  • 30
    Khare SD, Krco CJ, Pawelski JR, Griffiths MM, Luthra HS, David CS. Oral administration of human collagen peptide 250-270 suppresses collagen-induced arthritis in DBA/1 mice by inhibiting a Th1 response. Arthritis Rheum 1994; 37 (Suppl.):S398.
  • 31
    Seki N, Sudo Y, Yoshioka T et al. Type II collagen-induced arthritis. I. Induction and perpetuation of arthritis require synergy between humoral and cell-mediated immunity. J Immunol 1988; 140:147784.
  • 32
    Thompson HSG, Henderson B, Spencer JM, Hobbs SM, Peppard JV, Staines NA. Tolerogenic activity of polymerised type II collagen in preventing collagen-induced arthritis in rats. Clin Exp Immunol 1988; 72:2025.
  • 33
    Thompson HSG, Staines NA. Suppression of collagen-induced arthritis with pergastrically or intravenously administered type II collagen. Agents and Actions 1986; 19: 3189.
  • 34
    Staines NA, Harper N, Ward FJ, Bansal S. Arthritis: animal models of oral tolerance. Ann New York Acad Sci 1996; in press.